Latest News and Press Releases

Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology Third product company from Replay expands use of next-generation high payload...

Replay receives $1.5 million grant for its hypoimmunogenic technology platform Replay developing uCell™, its universal, off-the-shelf, genomically rewritten, renewable cell source hypoimmunogenic...

Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases Second product company using Replay’s next-generation high payload capacity HSV delivery vector developed at...

Replay launches its first HSV gene therapy company, Eudora, focused on retinal eye disease First product company using Replay’s high payload capacity HSV vectorUtilizes a next-generation HSV...

Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts San Diego, California and London, UK, October 17, 2022 – Replay, a genome writing company...

         Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA KKR and OMX Ventures lead $55 million seed funding roundReplay’s genomic medicine toolkit...

         Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA KKR and OMX Ventures lead $55 million seed funding roundReplay’s genomic medicine toolkit...